Candriam SCA’s Integra LifeSciences IART Stock Holding History

Candriam SCA’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9,000	Closed	-$500K	–	774
2019 Q2	$500K	Buy	+9,000	New	+$463K	0.01%	730

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Candriam SCA's IART Position: Q3 2019 in Review

Candriam SCA sold out of Integra LifeSciences (IART) in Q3 2019, closing a stake of 9,000 shares — an estimated $500K sold.

Candriam SCA first reported a position in IART in Q2 2019 and held it in 1 quarter. The position peaked at $500K in Q2 2019. 280 funds tracked by Wall St. Rank hold IART as of Q3 2019.

Candriam SCA reported no remaining Integra LifeSciences position as of Q3 2019 after selling out during the quarter.
Candriam SCA sold 9,000 Integra LifeSciences shares in Q3 2019, an estimated $500K.
Candriam SCA first reported a position in Integra LifeSciences in Q2 2019 and held it in 1 quarter.
Candriam SCA's Integra LifeSciences position peaked at $500K in Q2 2019.
280 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2019.

Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.